The prognosticator behind that piece of bad news was Citigroup's Joanne Wuensch, who issued one of her bank's 90-day catalyst watches on Tandem stock before the market open. Wuensch wrote in her ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the price target to $39.00 from $0.00. Jeff Johnson has given ...

大摩：维持Tandem Diabetes Care(TNDM.US)评级，由持股观望调整至持股观望评级, 目标价由45.00美元调整至45.00美元。 Tandem Diabetes Care（TNDM.US）公司简介 ...

RBC sets a $65 price target for Tandem, citing strong growth prospects and margin improvements. RBC expects 51% gross margins in 2024, with the Mobi pump launch driving long-term profitability.

In its press release trumpeting the EU's move, Tandem quoted its chief medical officer Jordan Pinsker as saying, "Ultra-rapid-acting insulin is a popular choice for people living with diabetes due ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tandem Diabetes Care (NASDAQ: TNDM) had some encouraging news to report on the regulatory front Thursday, and after it hit ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN DIEGO, September 19, 2024--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin ...

Worldwide Sales Growth: 12% growth, reaching $222 million in Q2 2024. Year-to-Date Worldwide Sales: $415 million with approximately 55,000 pump shipments. US Sales: $157 million in Q2, 20% ...